1. Home
  2. CTRI vs MESO Comparison

CTRI vs MESO Comparison

Compare CTRI & MESO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Centuri Holdings Inc. Common Stock

CTRI

Centuri Holdings Inc. Common Stock

HOLD

Current Price

$25.85

Market Cap

1.8B

Sector

N/A

ML Signal

HOLD

Logo Mesoblast Limited

MESO

Mesoblast Limited

HOLD

Current Price

$18.08

Market Cap

1.8B

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
CTRI
MESO
Founded
1909
2004
Country
United States
Australia
Employees
N/A
N/A
Industry
Biotechnology: Biological Products (No Diagnostic Substances)
Sector
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
1.8B
1.8B
IPO Year
2024
N/A

Fundamental Metrics

Financial Performance
Metric
CTRI
MESO
Price
$25.85
$18.08
Analyst Decision
Hold
Strong Buy
Analyst Count
4
2
Target Price
$23.25
$24.00
AVG Volume (30 Days)
2.2M
185.3K
Earning Date
11-05-2025
08-28-2025
Dividend Yield
N/A
N/A
EPS Growth
N/A
N/A
EPS
0.03
N/A
Revenue
$2,841,255,000.00
$17,198,000.00
Revenue This Year
$10.61
$465.44
Revenue Next Year
$9.02
$75.37
P/E Ratio
$1,021.94
N/A
Revenue Growth
9.89
191.39
52 Week Low
$14.46
$9.61
52 Week High
$26.17
$22.00

Technical Indicators

Market Signals
Indicator
CTRI
MESO
Relative Strength Index (RSI) 75.52 64.81
Support Level $19.04 $16.43
Resistance Level $20.76 $17.65
Average True Range (ATR) 0.94 0.62
MACD 0.55 0.30
Stochastic Oscillator 95.58 93.07

Price Performance

Historical Comparison
CTRI
MESO

About CTRI Centuri Holdings Inc. Common Stock

Centuri Holdings Inc is a pure-play North American utility infrastructure services company that partners with regulated utilities to maintain, upgrade and expand the energy network that powers millions of homes and businesses. Its service offerings consist of the modernization of utility infrastructure through the maintenance, retrofitting and installation of electric and natural gas distribution networks to meet current and future demands while also preparing systems for the transition to clean energy sources. It operates under two primary lines of business which includes Gas Utility Services and Electric Utility Services it is also their two reportable segments as well.

About MESO Mesoblast Limited

Mesoblast Ltd is a commercial-stage biotechnology company and a world leader in developing allogeneic (off-the-shelf) cellular medicines for the treatment of severe and life-threatening inflammatory conditions. The company's product candidates include: Ryoncil (remestemcel-L) for the treatment of steroid-refractory acute graft versus host disease, as well as for the treatment of moderate to severe acute respiratory distress syndrome; Revascor (rexlemestrocel-L) for the treatment of chronic heart failure; and Rexlemestrocel-L for chronic low back pain. The company is managed as one operating segment, being the development of an adult stem cell technology platform for commercialization.

Share on Social Networks: